PRODUCT INFORMATION



Histone H3 Polyclonal Antibody

Item No. 13781

Overview and Properties

This vial contains 500 µg of protein-A purified polyclonal antibody. Contents:

Synonym:

Immunogen: Recombinant Histone H3 Protein

Cross Reactivity: (-) H2A, H2B, and H4 Species Reactivity: (+) Human H3 **Uniprot No.:** P68431

Form: Liquid

-20°C (as supplied) Storage:

Stability: ≥3 years


Storage Buffer: PBS, pH 7.2, with 50% glycerol, 0.1% BSA, and 0.02% sodium azide

Rabbit Host:

ELISA, Flow Cytometry (FC), Immunoprecipitation (IP), and Western blot (WB); Applications:


> the recommended starting dilution for ELISA and WB is 1:200, 1:1000 for FC, and 20 µg of antibody per test for IP. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

Images



Lane 1: Recombinant Human Histone H3 (25 ng) Lane 2: Recombinant Human Histone H3 (50 ng)

Lane 3: Core Histones (10 ng) Lane 4: Core Histones (20 ng) Lane 5: Raji Cell Lystes (50 µg) Lane 6: A431 Cell Lysates (50 µg)



Sample Name	Subset Name	Count	
2017-06-26A1.0010.fcs	Ungated	26503	A1.010 - HeLa H3 (10 μg)
2017-06-26A1.0009.fcs	Ungated	33440	A1.009 – HeLa H3 (5 μg)
2017-06-26A1.0008.fcs	Ungated	41028	A1.008 – HeLa H3 (1 μg)
2017-06-26A1.0007.fcs	Ungated	46290	A1.007 – HeLa Secondary Alone
2017-06-26A1.0006.fcs	Ungated	39048	A1.006 - HeLa PBS

Flow Cytometry: HeLa cells were PFA fixed and permeabilized followed by a fetal bovine serum block. Cells were probed with the indicated antibody and analyzed using a Miltenyi MACSQuant

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Histone H3 is a nuclear protein and a component of the nucleosome core, a basic unit of chromatin, that is essential for organizing genomic DNA in eukaryotic nuclei. It is a globular protein that contains an unstructured N-terminal tail that extends outside of the nucleosome core and is subject to various post-translational modifications (PTMs), including methylation, phosphorylation, acetylation, and citrullination. Histone H3 PTMs function as epigenetic regulators of gene transcription by affecting chromatin structure and providing binding sites for many transcription factors, thus regulating several cellular functions including gene expression, cell cycle, and DNA replication and repair. Differential methylation of histone H3 at various lysine residues is catalyzed by SET domain-containing methyltransferases and marks sites of transcriptional activation or repression. Citrullination of histone H3 by protein arginine deiminase 4 (PAD4; Item Nos. 10500 | 25915 | 28910) or PAD2 (Item No. 10785) induces the release of neutrophil extracellular traps (NETs), a network of decondensed DNA and intracellular proteins secreted by neutrophils as a pathogen defense mechanism. Histone H3 mutations have been found in patients with diffuse intrinsic pontine glioma, leukemia, or chondroblastoma. Cayman's Histone H3 Polyclonal Antibody can be used for ELISA, flow cytometry (FC), immunoprecipitation (IP), and Western blot (WB) applications. The antibody recognizes histone H3 at 15.5 kDa from human samples.

References

- 1. Hyun, K., Jeon, J., Park, K., et al. Writing, erasing and reading histone lysine methylations. Exp. Mol. Med. 49(4), e324 (2017).
- 2. Sharda, A., Amnekar, R.V., Natu, A., et al. Histone posttranslational modifications: Potential role in diagnosis, prognosis, and therapeutics of cancer. Academic Press. (2019).
- 3. Filipescu, D., Müller, S., and Almouzni, G. Histone H3 variants and their chaperones during development and disease: Contributing to epigenetic control. *Annu. Rev. Cell Dev. Biol.* **30**, 615-646 (2014).
- 4. Leshner, M., Wang, S., Lewis, C., et al. PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front. Immunol. 3, 307 (2012).
- 5. Liang, Y., Pan, B., Alam, H.B., *et al.* Inhibition of peptidylarginine deiminase alleviates LPS-induced pulmonary dysfunction and improves survival in a mouse model of lethal endotoxemia. *Eur. J. Pharmacol.* 833, 432-440 (2018).
- 6. Lowe, B.R., Maxham, L.A., Hamey, J.J., et al. Histone H3 mutations: An updated view of their role in chromatin deregulation and cancer. *Cancers (Basel)* **11(5)**, 660 (2019).
- 7. Wan, Y.C.E., Liu, J., and Chan, K.M. Histone H3 mutations in cancer. *Curr. Pharmacol. Rep.* **4(4)**, 292-300 (2018).

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897